Stoke Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
STOK Nasdaq 8731 https://www.stoketherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Stoke Therapeutics Inc

How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91% - May 9th, 2023 1:55 pm
New Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK) - May 9th, 2023 10:04 am
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their Estimates - May 6th, 2023 12:03 pm
Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for - May 4th, 2023 2:00 pm
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - May 4th, 2023 12:55 pm
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates - May 4th, 2023 11:00 am
Stoke Therapeutics to Present at the BofA Securities Health Care Conference - May 3rd, 2023 12:00 pm
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? - May 2nd, 2023 2:02 pm
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom - Apr 25th, 2023 11:00 am
Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years - Mar 28th, 2023 2:40 pm
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome - Mar 15th, 2023 11:00 am
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates - Mar 6th, 2023 1:15 pm
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates - Mar 6th, 2023 12:00 pm
Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Feb 27th, 2023 9:30 pm
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference - Feb 7th, 2023 1:00 pm
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth - Jan 26th, 2023 10:59 am
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023 - Jan 9th, 2023 1:00 pm
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 1:00 pm
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting - Dec 2nd, 2022 2:00 pm
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting - Nov 29th, 2022 12:30 pm